Bristol Myer Stock Gets a Bump on FDA Approval for Schizophrenia Drug: Is it Time to Buy BMY?
Late last week Bristol Myers Squibb (BMY) got a nice 8% boost after sharing news that it gained approval from the Food and Drug Administration (FDA) for its schizophrenia drug. The stock has cooled off since and is up just shy of 4% over the past week, but it has been on a serious [...]
